Female, n (%) |
122 (63.9%) |
34 (81.0%) |
88 (59.1%) |
2.95 (1.28
to 6.80) |
0.009 |
Age, mean (SD), years |
|
|
|
|
|
At onset |
7.9 (3.9) |
9.7 (3.4) |
7.3 (3.8) |
-2.38 (-3.58 to -1.16) |
< 0.001 |
At HCQ initiation |
- |
12.0 (2.4) |
- |
- |
- |
Interval from ITP onset to HCQ initiation, mean (SD), months |
- |
26.4
(24.2) |
- |
- |
- |
Platelet counts, mean (SD), 109/L |
|
|
|
|
|
At onset |
26 (23) |
25 (22) |
26 (23) |
1.44 (-7.20 to 10.08) |
0.74 |
At HCQ initiation |
- |
85 (77) |
- |
- |
- |
Symptoms associated with autoimmune diseases *, n (%) |
55 (28.8%) |
20 (47.6%) |
35 (23.5%) |
2.96 (1.45 to 6.05) |
0.002 |
Positive ANA at baseline, n (%) |
67 (35.1%) |
21 (50.0%) |
46
(30.9%) |
2.24 (1.12 to 4.50) |
0.02 |
Other markers associated with autoimmune diseases, n (%) |
82/177
(46.3%) |
27 (64.3%) |
55/135 (40.7%) |
2.62 (1.28 to 5.37) |
0.008 |
Positive antiphospholipid antibodies †
|
50/163
(30.7%) |
20 (47.6%) |
30/121 (24.8%) |
2.76 (1.33 to 5.74) |
0.006 |
Low C3/C4 |
51/131 (38.9%) |
15/39 (38.5%) |
36/92 (39.1%) |
0.97
(0.45 to 2.10) |
0.94 |
Previous treatments, n (%) |
|
|
|
|
|
Corticosteroids |
159 (83.2%) |
32 (76.2%) |
127 (85.2%) |
- |
- |
IVIG |
133 (69.6%) |
27 (64.3%) |
106 (71.1%) |
- |
- |
Rituximab |
27 (14.1%) |
3 (7.1%) |
24 (16.1%) |
- |
- |
TPO-RAs |
33 (17.3%) |
4 (9.5%) |
29 (19.5%) |
- |
- |
Splenectomy |
2 (1.0%) |
1 (2.4%) |
1 (0.7%) |
- |
- |
Follow-up time, median (range), months |
37 (12 ~ 160) |
56 (17 ~ 146) |
34 (12 ~ 160) |
- |
- |
Response evaluated at last follow-up ‡, n (%) |
111
(58.1%) |
29 (69.0%) |
72 (48.3%) |
2.39 (1.15 to 4.95) |
0.02 |
CR at last follow-up, n (%) |
73 (38.2%) |
22 (52.4%) |
51 (34.2%) |
2.11 (1.06 to 4.23) |
0.03 |